Print

Synergy Pharmaceuticals Completes Screening and Planned Enrollment in Phase IIb/III Study in Chronic Idiopathic Constipation Patients  
8/14/2012 9:35:30 AM

NEW YORK, Aug. 14, 2012 (GLOBE NEWSWIRE) -- Synergy Pharmaceuticals Inc. (Nasdaq:SGYP), a developer of new drugs to treat gastrointestinal disorders announced today that its Phase IIb/III plecanatide study in chronic idiopathic constipation (CIC) achieved its enrollment target of 880 patients on August 13, 2012. Sites have been notified that screening will close August 16th and enrollment will close at the end of the month.
//-->